Articles Service - Marketing And Unique Articles - Online Directory - Quick Promotion - Free Contents


   

FDA Resolves Compliance Issues With Drug/Device Combination Products



[Valid RSS feed]  Category Rss Feed - http://www.look4articles.com/rss.php?rss=285
By : Nigel Smart    99 or more times read
Submitted 2009-11-15 09:50:44
Drug/device combination products raise compliance and regulatory issues in the pharmaceutical industry. On their own, each drug and device has their own specific type of marketing and good manufacturing practices regulation. However, when drugs and devices are combined together, they pose a new compliance question – how will this new combined product be regulated as a whole? Pharmaceutical consultants point out there isn’t one easy solution.

Combination products consist of the following: products that are combined with two or more regulated drugs, devices or biologics (i.e. drug/device, biologic/drug, or drug/device/biologic). Because of the diversity of these drug/device combinations, a one size fits all approach doesn’t always work. For example, these drug/device products may consist of either drugs packaged along with devices, or the drugs coated on devices. Another combination is drugs and devices that are packaged separately. These separate drugs and devices may be produced by different manufacturers.

Another issue that arises is the complexity of drug/device combinations. Combined products could be as simple as a syringe pre filled with drugs. They also could be as complex as chemotherapeutic drugs combined with monoclonal antibodies.

The U.S. Federal Drug Administration (FDA) has made it a top priority to address these ongoing compliance issues. They developed the Office of Combined Products (OCP) which was a result of the Medical Device User Fee and Modernization Act of 2002 (MDUFMA). The OCP has taken the mystery out of the compliance process for drug/device combinations, and has proved successful.

The OCP’s main priority is to ensure that these combined products are sent to the appropriate FDA Centers. They oversee timely premarket reviews of combination products. The OCP also oversees consistent, effective post market regulations.

However, OCP doesn’t handle the entire process associated with drug/device combination product compliance. They first determine the drug/device product’s “primary mode of action.” The OCP analyzes what is the “most important therapeutic action of a combination product.” Based on this “primary mode of action,” the OCP directs these drug/device products to the following Centers based on their analysis. The responsibility lies on the following FDA centers: Center for Biologics Evaluation and Research (CBER), Center for Drug Evaluation and Research (CDER), and Center for Devices and Radiological Health (CDRH).

Because of the regulatory complications associated with combination products, the FDA created an effective way to handle this problem. The OCP wrote a SOP for IntercenterConsultative/Collaborative Review Process. It outlines the necessary procedures and processes that the three Centers must follow when reviewing combination products.

The FDA also consults with applicants and assists them with marketing applications. According to the FDA, single marketing applications for combination products usually work for clearance. Dependent upon the combination product, the FDA may recommend two separate marketing applications. The FDA advises applicants to contact the OCP to discuss the appropriate marketing application based upon their drug/device combination.

Pharmaceutical consultants agree that the FDA’s OCP has made great strides over the past few years with compliance issues for drug/device products. The OCP conducts trainings for both staff and applicants throughout the year to resolve combination product issues.

If you liked this article, tell all your friends about it. They’ll thank you for it. If you have a blog or website, you can link to it or even post it to your own site (don’t forget to mention www.smartconsultinggrp.com as the original source.

Author Resource:

Nigel Smart is a pharmaceutical consultant with extensive experience in the biotechnology and pharmaceutical industry. With Denise Smart, he manages Smart Consulting Group. Visit their blog at http://www.smartconsultinggroup.com/blog

Related Articles


HTML Ready Article. Click on the "Copy" button to copy into your clipboard.




Firefox users please select/copy/paste as usual


New Members
select
Sign up
select
Learn more
ASK It!
ASK It!

 
Directory Menu
Home
Login to Directory
Submit Articles
Submission Guidelines
Top Articles
Link Directory
About Us
Articles Directory Advertisement
Articles Directory Advertisement Media Kit
Contact Us
Privacy Policy
RSS Feeds


Categories

Accessories
Advice
Aging
Arts
Arts and Crafts
Automotive
Break-up
Business
Business Management
Cancer Survival
Career
Cars and Trucks
CGI
Cheating
Coding Sites
Computers
Computers and Technology
Cooking
Crafts
Culture
Current Affairs
Databases
Death
Education
Entertainment
Etiquette
Family Concerns
Film
Finances
Food and Drinks
Gardening
Healthy Living
Holidays
Home
Home Management
Internet
Jobs
Leadership
Legal
Medical
Medical Business
Medicines and Remedies
Men Only
Motorcyles
Opinions
Our Pets
Outdoors
Parenting
Pets
Recreation
Relationships
Religion
Self Help
Self Improvement
Society
Sports
Staying Fit
Technology
Travel
Web Design
Weddings
Wellness, Fitness and Di
Women Only
Womens Interest
World Affairs
Writing
 
Actions
Print This Article
Add To Favorites
[Valid RSS feed]

Copyright LOOK 4 ARTICLES FREE DIRECTORY - 2005-2012 - Powered By: HYIP